Ok Jun Lee | Cancer Biotechnology | Innovative Research Award

Published on by Biotechnology Scientist

Innovative Research Award

Ok Jun Lee
Researcher Ok Jun Lee
Affiliation Chungbuk National University College of Medicine
Country South Korea
Scopus ID 7103020256
Documents 133
Citations 5,487
h-index 32
Subject Area Cancer Biotechnology
Event Biotechnology Scientist Awards
ORCID 0000-0002-5350-8751

Ok Jun Lee
Chungbuk National University College of Medicine, South Korea.

Ok Jun Lee is a researcher affiliated with Chungbuk National University College of Medicine, South Korea, whose scholarly work has contributed to the advancement of cancer biotechnology, molecular oncology, and translational biomedical research. The recognition presented through the Innovative Research Award highlights sustained academic productivity, scientific influence, and contribution to biotechnology-focused research initiatives.[1]

Abstract

This article presents a scholarly overview of Ok Jun Lee and the academic accomplishments associated with the Innovative Research Award. The profile examines research productivity, publication output, citation influence, and contributions to cancer biotechnology. The assessment reflects recognized indicators of scientific achievement, including peer-reviewed publications, citation performance, and sustained engagement in biomedical innovation.[1][2]

Keywords

Cancer Biotechnology; Molecular Oncology; Translational Medicine; Biomedical Research; Cancer Biomarkers; Biotechnology Innovation; Precision Medicine; Scientific Impact; Academic Excellence; Research Recognition.

Introduction

Biotechnology continues to play a central role in advancing healthcare through the development of diagnostic tools, therapeutic approaches, and molecular-level understanding of disease mechanisms. Researchers working within cancer biotechnology contribute to the identification of biomarkers, signaling pathways, and translational strategies aimed at improving patient outcomes. Within this context, Ok Jun Lee’s publication record demonstrates active participation in scientific investigations that align with contemporary challenges in oncology and biomedical sciences.[2][3]

Research Profile

Ok Jun Lee is affiliated with Chungbuk National University College of Medicine and has established a substantial research portfolio reflected through 133 indexed scholarly documents. The researcher’s citation performance exceeds 5,400 citations, while an h-index of 32 indicates consistent scholarly influence across multiple publications. Such indicators are commonly used in academic evaluation frameworks to assess research visibility and impact within scientific communities.[1][4]

The principal subject area associated with this profile is cancer biotechnology, encompassing investigations related to cancer biology, molecular diagnostics, therapeutic targets, and translational research methodologies. The interdisciplinary nature of biotechnology allows findings from laboratory studies to support clinical and healthcare applications.[3]

Research Contributions

The research contributions associated with Ok Jun Lee encompass scientific studies addressing molecular mechanisms involved in cancer progression, cellular regulation, and biomarker discovery. Publications within cancer biotechnology frequently contribute to the broader understanding of disease pathogenesis and therapeutic development.[5]

Additional scholarly activities include participation in collaborative research networks, peer-reviewed publication efforts, and dissemination of scientific findings through recognized academic channels. Such contributions support knowledge exchange and encourage innovation across biotechnology-related disciplines.[2]

Publications

The publication portfolio attributed to the researcher includes peer-reviewed journal articles and collaborative scientific studies indexed within major academic databases. Research outputs demonstrate sustained engagement with biotechnology and cancer-focused investigations, contributing to cumulative scientific knowledge and citation growth over time.[1][5]

  • Peer-reviewed oncology and biotechnology publications.
  • Collaborative multidisciplinary research studies.
  • Scientific articles focusing on molecular and translational medicine.
  • Research outputs contributing to citation-based scholarly impact.

Research Impact

Research impact may be assessed through citation metrics, publication quality, collaborative engagement, and knowledge translation. With more than 5,487 citations generated across thousands of citing documents, the scholarly work associated with Ok Jun Lee demonstrates visibility within the international research community. Citation-based indicators suggest that published findings have informed subsequent investigations and contributed to ongoing scientific discourse.[1][4]

Award Suitability

The Innovative Research Award recognizes researchers whose academic records demonstrate measurable contributions to scientific advancement. Based on documented publication output, citation performance, and engagement within cancer biotechnology, Ok Jun Lee presents characteristics commonly associated with candidates for academic recognition programs. Evaluation criteria such as scholarly productivity, research quality, and scientific influence align with the objectives of biotechnology-focused award initiatives.[1]

Conclusion

Ok Jun Lee’s academic profile reflects sustained involvement in cancer biotechnology research through a substantial body of publications, strong citation performance, and interdisciplinary scientific contributions. The Innovative Research Award profile serves as a structured overview of scholarly achievements and highlights the continuing importance of biotechnology research in advancing biomedical knowledge and healthcare innovation.[1][3]

References

    1. Elsevier. (n.d.). Scopus Author Details: Ok Jun Lee, Author ID 7103020256. Scopus Database.
      https://www.scopus.com/authid/detail.uri?authorId=7103020256
    2. ORCID. (n.d.). ORCID Record for Ok Jun Lee.
      https://orcid.org/0000-0002-5350-8751
    3. National Cancer Institute. (n.d.). Cancer Research and Biotechnology Resources.
      https://www.cancer.gov/research
    4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output.
    5. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation.

Chao Gao | Cancer Biotechnology | Young Researcher Award

Published on by Biotechnology Scientist

Dr. Chao Gao | Cancer Biotechnology | Young Researcher Award

Postdoctoral Fellow at Zhongshan Hospital | Fudan University | China

Dr. Chao Gao is a dedicated researcher specializing in liver cancer biology, small molecule drug development, and clinical translation of novel therapeutics. With strong expertise in biochemistry, structural biology, metabolomics, and drug resistance mechanisms, his career integrates fundamental science with translational applications. His work has significantly contributed to understanding tumor resistance pathways, biomarker discovery, and therapeutic strategies aimed at improving treatment outcomes in hepatocellular carcinoma and related malignancies. Currently serving as a Research Associate at the Liver Cancer Institute of Zhongshan Hospital, Fudan University, he continues to bridge cutting-edge laboratory research with clinical medicine.

Profile

Scopus

Education

Dr. Chao Gao earned his Bachelor’s degree in Pharmacy from Shandong University, where he ranked in the top of his class and focused on organic chemistry, exploring the extraction and bioactivity of natural plant compounds. He then pursued doctoral studies at Fudan University, obtaining his Ph.D. in Biochemistry and Molecular Biology with top distinction. His doctoral work under Prof. Fan Jia centered on liver cancer metabolism, therapeutic target identification, and molecular mechanisms of disease progression. Earlier in his doctoral training under Prof. Xu Yanhui, he gained expertise in structural biology and Cryo-EM approaches for understanding protein structure in DNA repair, epigenetics, and neurodegenerative disease contexts.

Experience

Following his Ph.D., Dr. Chao Gao served as a Postdoctoral Fellow in the Department of Liver Surgery and Transplantation at Zhongshan Hospital. His research focused on the drug resistance mechanisms of hepatocellular carcinoma, where he successfully identified tumor drug resistance targets via single-cell transcriptomics and developed potential small-molecule inhibitors for clinical application. he transitioned to the role of Research Associate at the same hospital, where he currently leads efforts in small molecule drug transformation and preclinical drug candidate development. His responsibilities include compound selection, hit validation, optimization, and Investigational New Drug (IND) application preparation, integrating multidisciplinary collaborations across toxicology, pharmacokinetics, and formulations. He has also contributed patents related to tumor drug resistance and targeted small-molecule inhibitors.

Research Interest

Dr. Chao Gao research interests lie at the intersection of tumor metabolism, drug resistance, and therapeutic innovation. He focuses on elucidating the molecular basis of hepatocellular carcinoma resistance to kinase inhibitors and immunotherapy, with the aim of developing targeted interventions that restore treatment efficacy. His projects extend to structural biology, exosome-mediated signaling, metabolic reprogramming, and immune microenvironment modulation. In addition, he explores CRISPR-based cancer models and multi-omics strategies, leveraging transcriptomics, proteomics, and metabolomics to uncover novel biomarkers and therapeutic targets. He is also deeply engaged in translational research, ensuring that his discoveries advance from bench to bedside.

Awards

Dr. Chao Gao has received numerous recognitions for his contributions to biomedical research. He was named one of the Top Ten Medical Youth of Fudan University, reflecting his impact and promise in clinical and translational medicine. He was awarded the Shanghai Postdoctoral Daily Funding Support, and earlier, the First-Class Scholarship for Outstanding Doctoral Candidates of Fudan University. His leadership and service were also acknowledged with titles such as Advanced Worker and Outstanding Individual of Fudan University Postgraduate Association. During his undergraduate years, he received the President Scholarship Candidate Award of Shandong University and the Provincial First Prize in the Challenge Cup.

Publications Top Notes

Dr. Chao Gao has published extensively in high-impact journals, advancing the understanding of liver cancer resistance and therapy. A representative selection of seven publications includes:

Title: KSR2-14-3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma.
Year: 2022

Title: Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Year: 2022

Title: Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
Year: 2020

Title: USP1 Maintains the Survival of Liver Circulating Tumor Cells by Deubiquitinating and Stabilizing TBLR1.
year: 2020

Title: Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
Year: 2021

Title: Structural insights into the activation of ATM kinase.
Year: 2019

Title: Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds.
Title: 2019

Conclusion

In summary, Dr. Chao Gao is an accomplished researcher who has made impactful contributions to the fields of liver cancer biology, structural biology, and translational therapeutics. His work integrates fundamental molecular research with clinical applications, particularly in combating drug resistance and enhancing immunotherapy efficacy. Through his leadership in national and institutional research projects, numerous high-impact publications, and recognition with prestigious awards, he continues to establish himself as a promising figure in biomedical research. With ongoing projects in multi-omics, drug resistance reversal, and immune microenvironment modulation, his career trajectory reflects both depth in scientific inquiry and commitment to translational medicine that directly benefits patient care.